WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will report third-quarter 2025 financial results before markets open on Tuesday, November 11, 2025. Company leadership will host a live investor conference call at 8:30 a.m. ET to review financial performance and provide a corporate update.
Investors can access the live webcast and presentation slides via the “Events & Presentations” section of Palvella’s website. Those who prefer to join by phone can register for dial-in details, and a replay of the webcast will be available for 90 days following the event.
Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on rare dermatologic diseases, continues to advance its QTORIN™ platform — a proprietary delivery system designed for serious, lifelong skin conditions that currently lack approved treatments. The company’s lead candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is being evaluated across multiple late-stage studies.
The pivotal Phase 3 SELVA trial is investigating QTORIN™ rapamycin in patients with microcystic lymphatic malformations, while the ongoing Phase 2 TOIVA trial is evaluating its potential in cutaneous venous malformations. A Phase 2 study in clinically significant angiokeratomas is also planned.
Founded by experts in rare disease drug development, Palvella aims to commercialize first-in-class therapies for serious skin disorders with limited treatment options. The company noted that QTORIN™ rapamycin remains an investigational product and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities for any indication.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.